BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ibudilast readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ibudilast\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05414240-8762@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibudilast: Phase 2 readout est. (NCT05414240)
DESCRIPTION:Ibudilast\, phase 2.\nStudy: Ibudilast for Treating Alcohol Use
  Disorder\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ibudilast#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05414240
URL:https://assetmemo.bio/drug/ibudilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04057898-8762@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibudilast: Phase 2/3 readout est. (NCT04057898)
DESCRIPTION:Ibudilast\, phase 2/3\, Amyotrophic Lateral Sclerosis.\nStudy: 
 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label E
 xtension for 6 Months in Patients With ALS\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibudilast
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040
 57898
URL:https://assetmemo.bio/drug/ibudilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
